2seventy bio Inc (NASDAQ: TSVT)’s stock price has soared by 0.10 in relation to previous closing price of 4.96. Nevertheless, the company has seen a gain of 0.30% in its stock price over the last five trading days. businesswire.com reported 2025-03-25 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. “2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma,” said Chip Baird, chief executive officer, 2seventy bio. “This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved.
Is It Worth Investing in 2seventy bio Inc (NASDAQ: TSVT) Right Now?
The 36-month beta value for TSVT is at 1.05. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TSVT is 47.46M, and currently, shorts hold a 6.98% of that float. The average trading volume for TSVT on April 03, 2025 was 1.06M shares.
TSVT’s Market Performance
The stock of 2seventy bio Inc (TSVT) has seen a 0.30% increase in the past week, with a 77.96% rise in the past month, and a 68.88% gain in the past quarter. The volatility ratio for the week is 0.28%, and the volatility levels for the past 30 days are at 1.90% for TSVT. The simple moving average for the past 20 days is 4.95% for TSVT’s stock, with a 25.55% simple moving average for the past 200 days.
Analysts’ Opinion of TSVT
Many brokerage firms have already submitted their reports for TSVT stocks, with Goldman repeating the rating for TSVT by listing it as a “Sell.” The predicted price for TSVT in the upcoming period, according to Goldman is $2 based on the research report published on June 06, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see TSVT reach a price target of $18, previously predicting the price at $5. The rating they have provided for TSVT stocks is “Outperform” according to the report published on January 31st, 2024.
TSVT Trading at 44.60% from the 50-Day Moving Average
After a stumble in the market that brought TSVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.85% of loss for the given period.
Volatility was left at 1.90%, however, over the last 30 days, the volatility rate increased by 0.28%, as shares surge +73.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +97.02% upper at present.
During the last 5 trading sessions, TSVT rose by +0.30%, which changed the moving average for the period of 200-days by +25.70% in comparison to the 20-day moving average, which settled at $4.73. In addition, 2seventy bio Inc saw 68.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSVT starting from Snow Jessica, who sale 2,298 shares at the price of $4.95 back on Mar 17 ’25. After this action, Snow Jessica now owns 254,193 shares of 2seventy bio Inc, valued at $11,364 using the latest closing price.
Baird William D III, the President and CEO of 2seventy bio Inc, sale 5,092 shares at $4.95 during a trade that took place back on Mar 17 ’25, which means that Baird William D III is holding 1,121,034 shares at $25,180 based on the most recent closing price.
Stock Fundamentals for TSVT
Current profitability levels for the company are sitting at:
- -2.81 for the present operating margin
- 0.35 for the gross margin
The net margin for 2seventy bio Inc stands at -1.51. The total capital return value is set at -0.24. Equity return is now at value -24.56, with -10.96 for asset returns.
Based on 2seventy bio Inc (TSVT), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35.
Currently, EBITDA for the company is -98.45 million with net debt to EBITDA at -1.76. When we switch over and look at the enterprise to sales, we see a ratio of 11.42. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
In conclusion, 2seventy bio Inc (TSVT) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
